+ Follow cardiovascular disease Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1932550
[Title] => COPD’s month of danger
[Summary] => New use of inhaled long-acting beta, agonists or long-acting antimuscarinic antagonists was associated with a 1.5-fold increased cardiovascular risk within 30 days of initiation in patients with chronic obstructive pulmonary disease, irrespective of prior cardiovascular disease status and history of exacerbations, according to a review of more than 280,000 COPD patients in Taiwan.
[DatePublished] => 2019-07-07 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 1917084
[Title] => ADA recommends cardioprotective antihyperglycemic drugs for patients
[Summary] => Recent studies that confirm the cardiovascular benefit of some antihyperglycemic agents are shaping the newest therapeutic recommendations for patients with type 2 diabetes and co-morbid atherosclerotic cardiovascular disease.
[DatePublished] => 2019-05-12 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[2] => Array
(
[ArticleID] => 1892382
[Title] => AACE: Updated lipid guidelines include ‘extreme risk’ category
[Summary] => Updated lipid management guidelines include a category of “extreme risk” patients in whom LDL cholesterol should be lowered below 55 mg/dL, according to a summary by the American Association of Clinical Endocrinologists and American College of Endocrinology.
[DatePublished] => 2019-02-10 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[3] => Array
(
[ArticleID] => 1820791
[Title] => EDITORIAL - Heartbreaker
[Summary] => The leading cause of death worldwide is cardiovascular disease, responsible for 44 percent or 17.9 million deaths annually from non-communicable diseases.
[DatePublished] => 2018-06-02 00:00:00
[ColumnID] => 0
[Focus] => 1
[AuthorID] =>
[AuthorName] =>
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] => http://media.philstar.com/images/articles/startoon_2018-06-01_20-57-54947_thumbnail.jpg
)
[4] => Array
(
[ArticleID] => 1237716
[Title] => ‘Morning Sex’ Last Part
[Summary] => Sa morning sex, gumaganda ang mood dahil sa serotonin levels na lumalabas sa sexual activity. Ang sex ay isang natural na paraan para gumanda ang mood dahil ang orgasm ay nagre-release ng mas maraming serotonin sa utak.
[DatePublished] => 2013-09-25 00:00:00
[ColumnID] => 134706
[Focus] => 0
[AuthorID] => 1525869
[AuthorName] => Miss ‘S’
[SectionName] => Para Malibang
[SectionUrl] => para-malibang
[URL] =>
)
[5] => Array
(
[ArticleID] => 448418
[Title] => Traffic jams could increase risk of heart attack: study
[Summary] => WASHINGTON (Xinhua) - People's risks of having a heart attack would be three times higher when they are caught by traffic jam for one hour, according to a German study published on the American Heart Association's website yesterday.
[DatePublished] => 2009-03-15 13:04:33
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[6] => Array
(
[ArticleID] => 234392
[Title] => GSK, Boehringer Ingelheim co-sponsor landmark trial
[Summary] => GlaxoSmithKline (GSK) joins forces with Boehringer Ingelheim (BI) to co-sponsor the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Program, the world’s largest ever cardiovascular protection trial using an angiotensin receptor blocker (ARB).
The program, which will enroll over 29,000 patients, will examine the preventive effects of telmisartan, either alone or in combination with the ACE inhibitor ramipril, on stroke, heart attack, cardiovascular death and hospitalization due to congestive heart failure.
[DatePublished] => 2004-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 231209
[Title] => Improving survival of high-risk heart patients
[Summary] => The greatest concern for high-risk heart patients is that their long-term survival may be significantly compromised.
Two of the world’s highly respected research-based pharmaceutical and healthcare companies have pooled their resources to sponsor what is believed to be the largest landmark cardiovascular protection trial of this decade which is expected to answer some questions on how to optimize cardiac care for patients at high risk and improve their long-term survival.
[DatePublished] => 2003-12-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 224399
[Title] => Trial seeks optimum hypertension mg’t
[Summary] => The growth in the medical understanding of heart disease that has been achieved with well-designed researches and clinical trials is one of the greatest achievements in medical history. Medical researchers all over the world have slowly but continuously provided the answers to many questions on heart-related diseases.
[DatePublished] => 2003-10-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[9] => Array
(
[ArticleID] => 221974
[Title] => ONTARGET: Protecting high-risk patients
[Summary] => Medical scientists and researchers are continuously undertaking researches and clinical trials which are answering a lot of previously unanswered questions in modern medicine.
Clinical trials have already convincingly shown that sustained management of hypertension significantly reduces the risk of cardiovascular events such as heart attack, heart failure, stroke and heart-related deaths.
Among the most effective medicines available to physicians is telmisartan, a medicine belonging to the angiotensin II receptor blocker class of drugs.
[DatePublished] => 2003-09-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
cardiovascular disease
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1932550
[Title] => COPD’s month of danger
[Summary] => New use of inhaled long-acting beta, agonists or long-acting antimuscarinic antagonists was associated with a 1.5-fold increased cardiovascular risk within 30 days of initiation in patients with chronic obstructive pulmonary disease, irrespective of prior cardiovascular disease status and history of exacerbations, according to a review of more than 280,000 COPD patients in Taiwan.
[DatePublished] => 2019-07-07 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 1917084
[Title] => ADA recommends cardioprotective antihyperglycemic drugs for patients
[Summary] => Recent studies that confirm the cardiovascular benefit of some antihyperglycemic agents are shaping the newest therapeutic recommendations for patients with type 2 diabetes and co-morbid atherosclerotic cardiovascular disease.
[DatePublished] => 2019-05-12 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[2] => Array
(
[ArticleID] => 1892382
[Title] => AACE: Updated lipid guidelines include ‘extreme risk’ category
[Summary] => Updated lipid management guidelines include a category of “extreme risk” patients in whom LDL cholesterol should be lowered below 55 mg/dL, according to a summary by the American Association of Clinical Endocrinologists and American College of Endocrinology.
[DatePublished] => 2019-02-10 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[3] => Array
(
[ArticleID] => 1820791
[Title] => EDITORIAL - Heartbreaker
[Summary] => The leading cause of death worldwide is cardiovascular disease, responsible for 44 percent or 17.9 million deaths annually from non-communicable diseases.
[DatePublished] => 2018-06-02 00:00:00
[ColumnID] => 0
[Focus] => 1
[AuthorID] =>
[AuthorName] =>
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] => http://media.philstar.com/images/articles/startoon_2018-06-01_20-57-54947_thumbnail.jpg
)
[4] => Array
(
[ArticleID] => 1237716
[Title] => ‘Morning Sex’ Last Part
[Summary] => Sa morning sex, gumaganda ang mood dahil sa serotonin levels na lumalabas sa sexual activity. Ang sex ay isang natural na paraan para gumanda ang mood dahil ang orgasm ay nagre-release ng mas maraming serotonin sa utak.
[DatePublished] => 2013-09-25 00:00:00
[ColumnID] => 134706
[Focus] => 0
[AuthorID] => 1525869
[AuthorName] => Miss ‘S’
[SectionName] => Para Malibang
[SectionUrl] => para-malibang
[URL] =>
)
[5] => Array
(
[ArticleID] => 448418
[Title] => Traffic jams could increase risk of heart attack: study
[Summary] => WASHINGTON (Xinhua) - People's risks of having a heart attack would be three times higher when they are caught by traffic jam for one hour, according to a German study published on the American Heart Association's website yesterday.
[DatePublished] => 2009-03-15 13:04:33
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[6] => Array
(
[ArticleID] => 234392
[Title] => GSK, Boehringer Ingelheim co-sponsor landmark trial
[Summary] => GlaxoSmithKline (GSK) joins forces with Boehringer Ingelheim (BI) to co-sponsor the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Program, the world’s largest ever cardiovascular protection trial using an angiotensin receptor blocker (ARB).
The program, which will enroll over 29,000 patients, will examine the preventive effects of telmisartan, either alone or in combination with the ACE inhibitor ramipril, on stroke, heart attack, cardiovascular death and hospitalization due to congestive heart failure.
[DatePublished] => 2004-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 231209
[Title] => Improving survival of high-risk heart patients
[Summary] => The greatest concern for high-risk heart patients is that their long-term survival may be significantly compromised.
Two of the world’s highly respected research-based pharmaceutical and healthcare companies have pooled their resources to sponsor what is believed to be the largest landmark cardiovascular protection trial of this decade which is expected to answer some questions on how to optimize cardiac care for patients at high risk and improve their long-term survival.
[DatePublished] => 2003-12-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 224399
[Title] => Trial seeks optimum hypertension mg’t
[Summary] => The growth in the medical understanding of heart disease that has been achieved with well-designed researches and clinical trials is one of the greatest achievements in medical history. Medical researchers all over the world have slowly but continuously provided the answers to many questions on heart-related diseases.
[DatePublished] => 2003-10-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[9] => Array
(
[ArticleID] => 221974
[Title] => ONTARGET: Protecting high-risk patients
[Summary] => Medical scientists and researchers are continuously undertaking researches and clinical trials which are answering a lot of previously unanswered questions in modern medicine.
Clinical trials have already convincingly shown that sustained management of hypertension significantly reduces the risk of cardiovascular events such as heart attack, heart failure, stroke and heart-related deaths.
Among the most effective medicines available to physicians is telmisartan, a medicine belonging to the angiotensin II receptor blocker class of drugs.
[DatePublished] => 2003-09-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
By
Miss ‘S’ | September 25, 2013 - 12:00am
January 8, 2004 - 12:00am
December 11, 2003 - 12:00am
October 16, 2003 - 12:00am
September 25, 2003 - 12:00am
